Eupraxia Pharmaceuticals Inc. is a clinical‑stage biotechnology company that leverages its proprietary DiffuSphere™ technology to optimize drug delivery for conditions with significant unmet medical need. The company’s lead product candidates are EP‑104GI, which is being developed for submucosal injection in the gastrointestinal tract to treat eosinophilic esophagitis, and EP‑104IAR, which is intended for intra‑articular injection to address chronic osteoarthritis pain in the knee. Both candidates utilize the same active pharmaceutical ingredient, fluticasone propionate, encapsulated within a polyvinyl alcohol polymer matrix to provide prolonged, steady drug release directly at the site of disease. Eupraxia remains pre‑revenue, with no products approved for commercial sale, and focuses its efforts on advancing these programs through clinical trials and partnership discussions.

Eupraxia currently generates no revenue from product sales because its candidates have not yet received marketing authorization. The company funds its research, development and operational activities primarily through equity financing and proceeds from private placements. It also evaluates potential collaboration and partnership arrangements that could provide milestone payments, licensing revenue or cost‑sharing arrangements to support continued development of EP‑104GI and EP‑104IAR. Until a product achieves regulatory approval, the company’s financial resources are devoted to clinical trial execution, manufacturing preparation and intellectual property maintenance.

The company operates through the following segments:

• EP-104GI: This segment focuses on the development of EP‑104GI for the treatment of eosinophilic esophagitis, a rare immune‑mediated disease characterized by esophageal inflammation and eosinophil infiltration. Activities include conducting a Phase 1b/2a clinical trial in Canada, the Netherlands, Australia and New Zealand, seeking pre‑IND feedback from the FDA, and exploring partnership opportunities to advance the program toward later‑stage studies and potential commercialization.

• EP-104IAR: This segment concentrates on EP‑104IAR for intra‑articular injection to treat knee osteoarthritis. The segment has completed a Phase 2b trial, held an FDA meeting to define late‑phase requirements for a New Drug Application, and is engaged in Phase 3 planning, manufacturing scale‑up and partnership evaluations to secure the resources needed for pivotal trials and possible commercial launch.

Within the biotechnology and drug‑delivery sectors, Eupraxia differentiates itself through its DiffuSphere™ technology, which enables a high proportion—over 90 % by weight—of the active corticosteroid fluticasone propionate to be delivered via a microparticle system that provides near‑constant drug levels over an extended period. This contrasts with conventional extended‑release formulations that typically contain less than 20 % active drug and rely on polymer degradation for release. While other companies pursue extended‑release corticosteroids or novel drug‑delivery platforms, Eupraxia’s proprietary membrane‑diffusion mechanism, combined with the established safety profile of fluticasone propionate, offers a potential advantage in minimizing systemic exposure and local tolerability issues for both eosinophilic esophagitis and osteoarthritis indications.

Eupraxia’s intended customer base comprises patients suffering from eosinophilic esophagitis or knee osteoarthritis, the physicians who treat these conditions—including gastroenterologists, allergists, rheumatologists and orthopaedic surgeons—and the healthcare institutions such as hospitals, clinics and infusion centers that would administer the injectable therapies. The company also anticipates engagement with managed‑care organizations and payer groups that evaluate coverage and reimbursement for novel specialty medicines once the products obtain regulatory approval.